Azenta Partners with PRECEDE Foundation to Enhance Pancreatic Cancer Detection and Prevention

Azenta Partners with PRECEDE Foundation to Combat Pancreatic Cancer

Azenta, Inc. announces a significant strategic partnership with the PRECEDE Foundation, aimed at transforming the landscape of pancreatic cancer detection and prevention. This collaboration emerges in light of the alarming statistics surrounding pancreatic cancer, which currently ranks as the third-leading cause of cancer-related deaths in the United States. Each year, over 66,500 individuals receive a diagnosis, yet the five-year survival rate remains dishearteningly low at just 13%. In comparison, other common cancers such as prostate, breast, and colon exhibit much higher survival rates, highlighting the urgent need for innovative approaches in this area.

The PRECEDE Foundation is dedicated to enhancing screening and prevention strategies for individuals at hereditary risk of pancreatic cancer. With the ambitious goal of increasing the five-year survival rate to 50% over the next decade, PRECEDE aims to leverage a robust network of over 60 leading academic medical centers worldwide. This initiative not only brings together significant expertise but also boasts the largest cohort of high-risk patients, utilizing longitudinal data and biospecimen tracking to drive advancements in early detection and treatment. Azenta’s role in this partnership includes providing secure storage solutions for crucial study samples within its biorepository, as well as managing logistics, which allows researchers to focus on improving diagnostics and patient outcomes.

Kathi Shea, Chief Client Solutions Officer at Azenta, emphasizes the critical nature of early detection in improving survival rates for pancreatic cancer. By aligning with PRECEDE’s mission, Azenta not only reinforces its commitment to supporting groundbreaking research but also solidifies its position as a key player in the biorepository sector. The partnership is a testament to Azenta's dedication to impactful life sciences research, showcasing its role as a trusted partner in facilitating advancements in health care. The PRECEDE Foundation is set to host its Annual Meeting this November, where experts will convene to discuss ongoing progress and collaborative strategies in the fight against pancreatic cancer.

In addition to its partnership with PRECEDE, Azenta remains focused on enhancing its biorepository capabilities to support various clinical and diagnostic endeavors. The company’s investment in secure and efficient storage solutions is vital for the future of medical research, particularly as the demand for high-quality biospecimens continues to rise. This alignment with PRECEDE not only enhances Azenta’s portfolio but also contributes to the broader goal of improving patient outcomes in a field that desperately needs innovation. For more details about the PRECEDE Foundation's initiatives, interested parties can visit their official website.